聯(lián)系方式 

郵箱：shiming@hit.edu.cn  

個(gè)人簡(jiǎn)介

2000-2004年：哈爾濱師范大學(xué) 生物技術(shù)學(xué)士

2005-2007年：哈爾濱工業(yè)大學(xué) 生物化學(xué)與分子生物學(xué)碩士

2007-2014年：哈藥集團生物工程有限公司/哈藥集團技術(shù)中心工程師

2009-2014年：哈爾濱工業(yè)大學(xué) 生物醫學(xué)工程博士

2011-2012年：美國德州A&M大學(xué) 聯(lián)合培養博士

2014-2017年：哈爾濱工業(yè)大學(xué) 生命科學(xué)與技術(shù)學(xué)院講師

2019-2020年：哈佛大學(xué) 醫學(xué)院訪(fǎng)問(wèn)學(xué)者

2018-至今：  哈爾濱工業(yè)大學(xué) 生命科學(xué)與技術(shù)學(xué)院副教授

Personal Profile 

2000-2004, B.S., Biotechnology, Harbin Normal University, China

2005-2007, M.S., Biochemistry and molecular biology, Harbin Institute of Technology, China

2007-2014, Engineer, Harbin pharmaceutical group bioengineering company, Harbin

2009-2014, Ph.D., Biomedical engineering, Harbin Institute of Technology, China

2011-2012, joint Ph.D., IBT - Texas A&M Health Science Center, Houston, TX, USA

2014-2017, Lecturer, Harbin Institute of Technology, Harbin

2019-2020, Visiting Associate Professor/Research Associate, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston

2018-Now, Associate professor, Harbin Institute of Technology, Harbin

研究方向和領(lǐng)域

腫瘤細胞生物學(xué)與腫瘤免疫學(xué)研究方向

1. 腫瘤發(fā)生的分子機制

2. 腫瘤免疫和腫瘤微環(huán)境

Research Area

Cancer cell biology and  Cancer immunology

1. Molecular mechanism of tumorigenesis

2. Cancer immunology and cancer microenvironment

研究?jì)热?/span>

1. 從事腫瘤相關(guān)基因的生物學(xué)功能研究，已發(fā)現MARVELD1基因在腫瘤細胞中表觀(guān)沉默的分子機制及臨床意義（Mol Carcinog, 2016&2019）；以及GAP43基因在結腸癌中的生物學(xué)作用(BMC cancer 2021）；

2. 在天然免疫模式識別受體PGLYRP2介導抗腫瘤天然免疫應答的研究中，發(fā)現PGLYRP2基因的表達與腫瘤微環(huán)境、腫瘤浸潤淋巴細胞之間的關(guān)系，明確了PGLYRP2蛋白對肝癌免疫應答的調控功能與具體機制（Hepatology, 2020），以及PGLYRP2蛋白作為腫瘤免疫標志物的潛在應用價(jià)值（國家發(fā)明專(zhuān)利，2019）。

Research Interests

1. Study the function of cancer-associated genes in tumorigenesis, and have found the role of MARVELD1 and GAP43 in cancer development (Mol Carcinog, 2016&2019; BMC cancer 2021).

2. Study the function of PGLYRP2 in cancer immunology, and have found the role of PGLYRP2 in regulating cancer immune microenvironment (Hepatology, 2020). PGLYRP2 acts as potential biomarker for adequate immune responses against cancer (patient 2019).

研究成果

1. Chen X#, Wu H#, Feng J#, Li Y, Lv J, Shi W, Fan W, Xiao L, Sun D, Jiang M*, Shi M*. Transcriptome profiling unveils GAP43 regulates ABC transporters and EIF2 signaling in colorectal cancer cells. BMC Cancer. 2021 Jan 5;21(1):24.

2. Yang Z#, Feng J#, Xiao L#, Chen X, Yao Y, Li Y, Tang Y, Zhang S, Lu M, Qian Y, Wu H*, Shi M*. Tumor-Derived Peptidoglycan Recognition Protein 2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology. 2020 May;71(5):1626-1642.

3. Shi M#,*, Zhang P#, Vora SM, Wu H*. Higher-order assemblies in innate immune and inflammatory signaling: A general principle in cell biology. Curr Opin Cell Biol. 2020 Apr;63:194-203.

4. Zhang C#, Han F#, Shi M#, Sun H, Li Y, Ci Y, Yao Y, Dou P, Akhtar ML, Nie H, He J, Li Y*. MARVELD1 interacting with catalase regulates reactive oxygen species metabolism and mediates the sensitivity to chemotherapeutic drugs in epithelial tumors of the reproductive system. Mol Carcinog. 2019 Aug;58(8):1410-1426.

5. Li K, Qu S, Chen X, Wu Q, Shi M*. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways. Int J Mol Sci. 2017 Feb 14;18(2).

6. Shi M, Chen X, Ye K, Yao Y, Li Y*. Application potential of toll-like receptors in cancer immunotherapy: Systematic review. Medicine (Baltimore). 2016 Jun;95(25):e3951.

7. Shi M, Zhang Y, Liu L, Zhang T, Han F, Wang F, McKeehan L. Wallace, Li Y*, Zhang D*. MAP1S controls bacterial phagocytosis through TLR signaling. J Biol. Chem. 2016 Jan 15;291(3):1243-50.

8. Yao Y#, Shi M#, Liu S, Li Y, Guo K, Ci Y, Liu W, Li Y*. MARVELD1 modulates cell surface morphology and suppresses epithelial-mesenchymal transition in non-small cell lung cancer. Mol Carcinog. 2016 Nov;55(11):1714-1727.

9. Shi M, Wang S, Yao Y, Li Y, Zhang H, Han F, Nie H, Su J, Wang Z, Yue L, Cao J, Li Y*. Biological and clinical significance of epigenetic silencing of MARVELD1 gene in lung cancer. Sci Rep. 18(4):7545, 2014.

10. Shi M, Yao Y, Han F, Li Y*. MAP1S Controls Breast Cancer Cell TLR5 Signaling Pathway and Promotes TLR5 Signaling-based Tumor Suppression. PloS One. 9(1):e86839, 2014.

11. Shi M, Yao Y, Li Y*. TLR5 signaling induces autophagic cell death to inhibit breast cancer via novel autophagic adaptor MAP1S. Clinical and Experimental Pharmacoogy and Physiology. 40(1): 03–18, 2013.

12. Wu J, Sun P, Chen Q, Sun Y, Shi M, Mang G, Yu S, Zheng Y, Li Z, Sun M, Fang S, Zhang Y, Tian J, Mingyan E, Zhang M, Yu B. Metabolic reprogramming orchestrates CD4 + T-cell immunological status and restores cardiac dysfunction in autoimmune induced-dilated cardiomyopathy mice. J Mol Cell Cardiol. 2019 Oct;135:134-148.

13. Li Y, Wu Y, Zhang X, Bai Y, Akthar LM, Lu X, Shi M, Zhao J, Jiang Q, Li Y. SCIA: A Novel Gene Set Analysis Applicable to Data With Different Characteristics. Front Genet. 2019 Jun 25;10:598.

14. Zhang H, Hua Y, Jiang Z, Yue J, Shi M, Zhen X, Zhang X, Yang L, Zhou R, Wu S. Cancer-associated Fibroblast-promoted LncRNA DNM3OS Confers Radioresistance by Regulating DNA Damage Response in Esophageal Squamous Cell Carcinoma. Clin Cancer Res. 2019 Mar 15;25(6):1989-2000.

15. Wu J, Zhang H, Zheng Y, Jin X, Liu M, Li S, Zhao Q, Liu X, Wang Y, Shi M, Zhang S, Tian J, Sun Y, Zhang M, Yu B. The Long Noncoding RNA MALAT1 Induces Tolerogenic Dendritic Cells and Regulatory T Cells via miR155/Dendritic Cell-Specific Intercellular Adhesion Molecule-3 Grabbing Nonintegrin/IL10 Axis. Front Immunol. 2018 Aug 13;9:1847.

16. Wang ZY, Shi M, Li Y*. Importin-β1 plays a key role in the nucleocytoplasmic transportation process of MARVELD1. Mol Biol. 49(3):491-7, 2015.

17. Lu X, Nie H, Li Y, Cao Z, Liu X, Shi X, Shi M, Zhang Y, Li Y*. Comprehensive characterization and evaluation of hepatocellular carcinoma by LC–MS based serum metabolomics. Metabolomics. DOI: 10.1007/s11306-015-0797-4, 2015.

18. Wang S, Hu J, Yao Y, Shi M, Yue L, Han F, Zhang H, He J, Liu S, Li Y*. MARVELD1 regulates integrin beta1-mediated cell adhesion and actin organization via inhibiting its pre-mRNA processing. Int J Biochem Cell Biol. 45(11):2679-2687, 2013.

開(kāi)設的課程

生物物質(zhì)分離工程

Biomass Separation Engineering

教師個(gè)人主頁(yè)鏈接

http://homepage.hit.edu.cn/SHIMING